Therefore, our findings suggest MET altered NSCLC tumors with high TWIST1 and low p27 expression maybe more sensitive to the combination of a CDK4/6 inhibitor alone or in combination with MET TKIs. The gene discussed is CDKN1B; the disease is non-small cell lung carcinoma.